LOGIN  |  REGISTER
Cue Biopharma

NeuroOne Medical Technologies to Participate in the 36th Annual Roth Conference

March 08, 2024 | Last Trade: US$0.76 0.00 0.00

EDEN PRAIRIE, Minn., March 08, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced its participation in the 36th Annual Roth Conference being held March 17-19, 2024 in Dana Point, California. Chief Executive Offer Dave Rosa and Chief Financial Officer Ron McClurg will host one-on-one meetings with institutional investors and analysts on Monday, March 18th and Tuesday, March 19th.

Conference Details: 

Location:The Ritz Carlton, Laguna Niguel in Dana Point, California.
Registration:Available on the conference website.
1x1 meetings:Investors may request a meeting by contacting a Roth representative at 800.678.9147 or by contacting NeuroOne investor relations.

About NeuroOne

NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit nmtc1.com

Contact:

800-631-4030
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Chimerix

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB